急性卒中治疗中阴性(非中性)试验的危害:综述
该综述回顾了急性卒中随机临床试验中导致结局恶化的阴性(非中性)干预,涉及神经保护、抗凝、抗炎、自由基清除、止血或血管活性等机制。在脑出血中血小板输注有害,而其他策略如物理治疗和降压药过早干预也可能有害。文章强调需从既往阴性试验中学习,改进未来研究设计。
要点
- 急性缺血性卒中多种干预在RCT中显示阴性(非中性)并恶化结局。
- 脑出血中血小板输注有害,其他策略过早干预也可能有害。
- 未来RCT需评估神经、血管、心脏及一般安全性,无论靶向或脱靶。
核心结论
- 从阴性卒中RCT中吸取的教训对设计未来研究至关重要。
- 需开展多中心临床前研究,并将死亡动物纳入分析。
- 所有临床前试验和RCT必须完整发表。
研究设计与样本
- 综述,回顾急性卒中随机临床试验中阴性(非中性)干预。
主要发现
- 急性缺血性卒中阴性(非中性)干预包括推定的神经保护、抗凝、抗炎、自由基清除、止血或血管活性药物。
- 其他药物降低溶栓效率或表现神经精神或心脏毒性。
- 脑出血中血小板输注有害。
- 再灌注治疗应尽早给予,但其他策略如物理治疗和降压药过早干预可能有害。
临床怎么用
- 临床应警惕急性卒中干预可能造成危害,避免过早使用非再灌注策略。
- 未来RCT需全面评估神经、血管、心脏及一般安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: While there are a limited number of beneficial treatments for acute stroke (eg, stroke units, reperfusion, aspirin, hemicraniectomy), there are more negative (as opposed to neutral) interventions spanning multiple different mechanisms of action. To reduce the risk of future negative studies, it is vital to understand why previous interventions appeared to cause harm. OBSERVATIONS: The limited number of beneficial treatments for acute ischemic stroke are far outnumbered by negative (not neutral) interventions that worsened outcomes in randomized clinical trials (RCTs), including those with putative neuroprotectant, anticoagulant, anti-inflammatory, free radical-scavenging, hemorrhagic, or vasoactive activity. Other agents reduced thrombolytic efficiency or exhibited neuropsychiatric or cardiac toxicity. In intracerebral hemorrhage, platelet transfusion was hazardous. Although reperfusion treatments should be given as soon as possible, very early intervention with other strategies may instead be hazardous, as has been seen with physical therapy and vasodepressors. CONCLUSIONS AND RELEVANCE: The lessons learned from negative stroke RCTs are vital for designing future studies. Multicenter preclinical studies are necessary, and animals that die must be included in analyses. Randomized clinical trials must assess multiple neurological, vascular, cardiac, and general safety effects, whether these are on target or off target. All preclinical trials and RCTs must be published in full. Learning from the past will help to reduce the number of negative stroke RCTs in the future.
引用
- Bath PM, Appleton JP, England T, et al. The Hazard of Negative (Not Neutral) Trials on Treatment of Acute Stroke: A Review. JAMA Neurol. 2020. PMID: 31790551. doi:10.1001/jamaneurol.2019.4107
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。